FATE THERAPEUTICS INC Debt Securities, Available-for-sale, Amortized Cost
FATE THERAPEUTICS INC (FATE) had Debt Securities, Available-for-sale, Amortized Cost of $53.18 million as of 2019-09-30, per its 10-Q filed 2019-11-05.
Discontinued › Notes › Credit Losses
us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis · last filed 2019-11-05
- 2019-09-30: Debt Securities, Available-for-sale, Amortized Cost $53.18M.
- 2019-06-30: Debt Securities, Available-for-sale, Amortized Cost $90.48M.
- 2018-12-31: Debt Securities, Available-for-sale, Amortized Cost $10.49M.
- 2018-09-30: Debt Securities, Available-for-sale, Amortized Cost $27.96M.
| Period end | Debt Securities, Available-for-sale, Amortized Cost |
|---|---|
| 2019-09-30 | $53.18M 10-Q · filed 2019-11-05 |
| 2019-06-30 | $90.48M 10-Q · filed 2019-08-06 |
| 2018-12-31 | $10.49M 10-Q · filed 2019-11-05 |
| 2018-09-30 | $27.96M 10-Q · filed 2018-11-01 |
| 2018-06-30 | $41.87M 10-Q · filed 2018-08-06 |
| 2017-12-31 | $12.00M 10-K · filed 2019-03-05 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Liminatus Pharma, Inc. (LIMN) | United States | $0.282B | |
| Lexeo Therapeutics, Inc. (LXEO) | United States | $0.278B | -4.19 |
| PALISADE BIO, INC. (PALI) | United States | $0.275B | -11.41 |
| Invivyd, Inc. (IVVD) | United States | $0.270B | -2.42 |
| Inhibikase Therapeutics, Inc. (IKT) | United States | $0.296B | -4.44 |
| X4 Pharmaceuticals, Inc (XFOR) | United States | $0.297B | -4.99 |
| SUTRO BIOPHARMA, INC. (STRO) | United States | $0.260B | -3.05 |
| SAB Biotherapeutics, Inc. (SABS) | United States | $0.306B | -25.49 |
| Century Therapeutics, Inc. (IPSC) | United States | $0.306B | -4.02 |
| Lineage Cell Therapeutics, Inc. (LCTX) | United States | $0.241B | -10.35 |